Eli Lilly and Company (LLY)

About Eli Lilly and Company

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

As of November 3, 2026, Eli Lilly and Company (LLY) stock edged lower to $1,410.99, down 0.46% (-$6.55) versus the previous close. On the day, shares have traded between $1,387.10 and $1,421.99. That puts LLY near the top of its 52-week range of $850.51 to $1,449.68. Eli Lilly and Company operates in the pharmaceutical preparations space and carries a market capitalization of roughly $1.26 trillion, with about 3.74 million shares changing hands.

Latest LLY news

• Eli Lilly Just Delivered Another Monster Quarter. But There’s More to This Story Than Weight-Loss Drugs247wallst.com· Nov 3, 8:03 AM ET
• How to Invest in the Rise of China’s Biotech: Buy U.S. Drug StocksYahoo Finance· Nov 3, 6:15 AM ET
• LLY Stock Up Almost 10% After a Robust Q3: Time to Buy, Sell or Hold?Yahoo Finance· Nov 3, 6:11 AM ET
• Eli Lilly Just Gained 22% in a Month: Take Profits, or Buy More?tikr.com· Nov 3, 6:08 AM ETNVO
• ETFs Bought $147.9 Million of Eli Lilly (LLY) on Oct. 30Yahoo Finance· Nov 3, 6:01 AM ET
• Clean Sweep for Seven Companies in Extel’s 2026 U.S. Corporates SurveyYahoo Finance· Nov 3, 5:20 AM ET
• Unprecedented weight-loss drug craze pushing Lilly to near-record highsthestreet.com· Nov 2, 10:03 PM ET
• Eli Lilly Stock: Is It Still a Buy at $1,400?fool.com· Nov 2, 6:20 PM ET

Source: Yahoo Finance RSS · Updated November 3, 2026

Want LLY headlines, alerts and AI research in one place? Create a free account →

• $ABCL $MRNA $REGN $SLS $LLY $ABCL 👀🔥 There is zero fundamental reason to support ABCL falling in price. If anything, the stock is too cheap right now. People don’t understand the sheer magnitude of what this company will do, and sadly those people will be left behind… I’m ju…

  @Stocktradesmoon· Nov 3, 8:29 AM ET· Bullish

• JPMorgan🏁 $TRXB and said--We are initiating coverage of TRexBio (TRXB) with an OW rating and a Dec- 2027 PT of $20. [ $JNJ $LLY [ABBV SNY - REGN PFE CRVS QTTB MANE NKTR CLDX Dren Bio, ALYS Pharma, Legacy Healthcare, Reistone, Suzhou, EVMN KYMR BCRX ACRX]] JPMorgan went on to …

  @Quantumup· Nov 3, 7:18 AM ET

• "$LLY: Buy, sell or hold after its 9.6% post-earnings rally? 🤔 🚀 Q3 revenue surged 39% year over year to $24.40B; full-year guidance raised to $91-92B. 💊 Mounjaro and Zepbound generated $43.8B in combined sales in the first nine months of 2026. ⚠️ Rising competition, 1…

  @ZacksResearch· Nov 3, 6:32 AM ET

• Liquidity Weighed On Gold Trumping Real Yields $IVW $VTV $GOOG $GOOGL $LLY https://talkmarkets.com/article/liquidity-weighed-on-gold-trumping-real-yields

  @TalkMarkets· Nov 3, 5:30 AM ET

• Dark pool volume in $LLY ran above normal, about 1.4x its usual pace. The full read shows the session-by-session dark pool share and which institutions are adding or cutting. The full dark-pool read, with the options side: https://globaltradersacademy.com/articles/dark-pool-ac…

  @GlobalTradersAcademy· Nov 3, 2:03 AM ET

Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →